Skip to main content
NCBI home page
The Yale Journal of Biology and Medicine logoLink to The Yale Journal of Biology and Medicine
. 1996 May-Jun;69(3):271–281.

Management of refractory and complicated reflux esophagitis.

B I Hirschowitz 1
PMCID: PMC2589006  PMID: 9165696

Abstract

Simple intermittent heartburn with minor or no esophagitis can be treated with simple measures including lifestyle changes and antacids as needed, or H2 receptor antagonists (H2RA), and has a good outcome. Problematic reflux includes resistance to therapy, stricture, Barrett's esophagus and aspiration. Severe reflux esophagitis, often resistant to H2RA therapy, requires more potent treatment with potent acid suppression using proton pump inhibitors, often indefinitely. When complicated by stricture, dilatations with potent acid suppression are needed. Barrett's esophagus is subject to esophagitis, which is no more difficult to treat than other cases of esophagitis. Reflux in Barrett's esophagus should be treated on its own merits without regard to the presence of Barrett's epithelium. Dysplasia leading to adenocarcinoma is a different problem, apparently not influenced by reduced exposure to acid. Indications for antireflux surgery are quite limited and should be carefully analyzed as a cost/risk/benefit problem.

Full text

PDF
271

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barham C. P., Gotley D. C., Mills A., Alderson D. Oesophageal acid clearance in patients with severe reflux oesophagitis. Br J Surg. 1995 Mar;82(3):333–337. doi: 10.1002/bjs.1800820317. [DOI] [PubMed] [Google Scholar]
  2. Behar J., Biancani P., Sheahan D. G. Evaluation of esophageal tests in the diagnosis of reflux esophagitis. Gastroenterology. 1976 Jul;71(1):9–15. [PubMed] [Google Scholar]
  3. Bell N. J., Burget D., Howden C. W., Wilkinson J., Hunt R. H. Appropriate acid suppression for the management of gastro-oesophageal reflux disease. Digestion. 1992;51 (Suppl 1):59–67. doi: 10.1159/000200917. [DOI] [PubMed] [Google Scholar]
  4. Bell N. J., Hunt R. H. Role of gastric acid suppression in the treatment of gastro-oesophageal reflux disease. Gut. 1992 Jan;33(1):118–124. doi: 10.1136/gut.33.1.118. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Berenson M. M., Johnson T. D., Markowitz N. R., Buchi K. N., Samowitz W. S. Restoration of squamous mucosa after ablation of Barrett's esophageal epithelium. Gastroenterology. 1993 Jun;104(6):1686–1691. doi: 10.1016/0016-5085(93)90646-t. [DOI] [PubMed] [Google Scholar]
  6. Bremner C. G., Lynch V. P., Ellis F. H., Jr Barrett's esophagus: congenital or acquired? An experimental study of esophageal mucosal regeneration in the dog. Surgery. 1970 Jul;68(1):209–216. [PubMed] [Google Scholar]
  7. Brown C. M., Rees W. D. Review article: factors protecting the oesophagus against acid-mediated injury. Aliment Pharmacol Ther. 1995 Jun;9(3):251–262. doi: 10.1111/j.1365-2036.1995.tb00379.x. [DOI] [PubMed] [Google Scholar]
  8. Brunnen P. L., Karmody A. M., Needham C. D. Severe peptic oesophagitis. Gut. 1969 Oct;10(10):831–837. doi: 10.1136/gut.10.10.831. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Cameron A. J., Lomboy C. T. Barrett's esophagus: age, prevalence, and extent of columnar epithelium. Gastroenterology. 1992 Oct;103(4):1241–1245. doi: 10.1016/0016-5085(92)91510-b. [DOI] [PubMed] [Google Scholar]
  10. Cameron A. J., Ott B. J., Payne W. S. The incidence of adenocarcinoma in columnar-lined (Barrett's) esophagus. N Engl J Med. 1985 Oct 3;313(14):857–859. doi: 10.1056/NEJM198510033131404. [DOI] [PubMed] [Google Scholar]
  11. Carr S. J., Wicks A. C. Omeprazole and oesophageal stricture. Lancet. 1992 Feb 1;339(8788):316–316. doi: 10.1016/0140-6736(92)91398-r. [DOI] [PubMed] [Google Scholar]
  12. Castell Donald O. Commentary: Over-the-Counter H(2)-Receptor Antagonists: Perhaps the Time Has Come! Am J Ther. 1995 May;2(5):303–303. [PubMed] [Google Scholar]
  13. Dahms B. B., Rothstein F. C. Barrett's esophagus in children: a consequence of chronic gastroesophageal reflux. Gastroenterology. 1984 Feb;86(2):318–323. [PubMed] [Google Scholar]
  14. Dent J., Bremner C. G., Collen M. J., Haggitt R. C., Spechler S. J. Barrett's oesophagus. J Gastroenterol Hepatol. 1991 Jan-Feb;6(1):1–22. doi: 10.1111/j.1440-1746.1991.tb01137.x. [DOI] [PubMed] [Google Scholar]
  15. Deviere J., Buset M., Dumonceau J. M., Rickaert F., Cremer M. Regression of Barrett's epithelium with omeprazole. N Engl J Med. 1989 Jun 1;320(22):1497–1498. doi: 10.1056/NEJM198906013202218. [DOI] [PubMed] [Google Scholar]
  16. Fennerty M. B., Sampliner R. E., Garewal H. S. Review article: Barrett's oesophagus--cancer risk, biology and therapeutic management. Aliment Pharmacol Ther. 1993 Aug;7(4):339–345. doi: 10.1111/j.1365-2036.1993.tb00107.x. [DOI] [PubMed] [Google Scholar]
  17. Gillen P., Keeling P., Byrne P. J., Hennessy T. P. Barrett's oesophagus: pH profile. Br J Surg. 1987 Sep;74(9):774–776. doi: 10.1002/bjs.1800740906. [DOI] [PubMed] [Google Scholar]
  18. Goldberg H. I., Dodds W. J., Gee S., Montgomery C., Zboralske F. F. Role of acid and pepsin in acute experimental esophagitis. Gastroenterology. 1969 Feb;56(2):223–230. [PubMed] [Google Scholar]
  19. Hamilton S. R., Hutcheon D. F., Ravich W. J., Cameron J. L., Paulson M. Adenocarcinoma in Barrett's esophagus after elimination of gastroesophageal reflux. Gastroenterology. 1984 Feb;86(2):356–360. [PubMed] [Google Scholar]
  20. Hetzel D. J. Controlled clinical trials of omeprazole in the long-term management of reflux disease. Digestion. 1992;51 (Suppl 1):35–42. doi: 10.1159/000200913. [DOI] [PubMed] [Google Scholar]
  21. Hetzel D. J., Dent J., Reed W. D., Narielvala F. M., Mackinnon M., McCarthy J. H., Mitchell B., Beveridge B. R., Laurence B. H., Gibson G. G. Healing and relapse of severe peptic esophagitis after treatment with omeprazole. Gastroenterology. 1988 Oct;95(4):903–912. doi: 10.1016/0016-5085(88)90162-x. [DOI] [PubMed] [Google Scholar]
  22. Hirschowitz B. I. A critical analysis, with appropriate controls, of gastric acid and pepsin secretion in clinical esophagitis. Gastroenterology. 1991 Nov;101(5):1149–1158. doi: 10.1016/0016-5085(91)90062-p. [DOI] [PubMed] [Google Scholar]
  23. Hirschowitz B. I. Gastric acid and pepsin secretion in patients with Barrett's esophagus and appropriate controls. Dig Dis Sci. 1996 Jul;41(7):1384–1391. doi: 10.1007/BF02088563. [DOI] [PubMed] [Google Scholar]
  24. Hirschowitz B. I. Medical management of esophageal reflux. Yale J Biol Med. 1994 May-Aug;67(3-4):223–231. [PMC free article] [PubMed] [Google Scholar]
  25. Hirschowitz B. I. Pathobiology and management of hypergastrinemia and the Zollinger-Ellison syndrome. Yale J Biol Med. 1992 Nov-Dec;65(6):659–692. [PMC free article] [PubMed] [Google Scholar]
  26. JOHNS B. A. E. Developmental changes in the oesophageal epithelium in man. J Anat. 1952 Oct;86(4):431–442. [PMC free article] [PubMed] [Google Scholar]
  27. Johnson N. J., Boyd E. J., Mills J. G., Wood J. R. Acute treatment of reflux oesophagitis: a multicentre trial to compare 150 mg ranitidine b.d. with 300 mg ranitidine q.d.s. Aliment Pharmacol Ther. 1989 Jun;3(3):259–266. doi: 10.1111/j.1365-2036.1989.tb00212.x. [DOI] [PubMed] [Google Scholar]
  28. Just R., Katzka D. A., Castell D. O. Omeprazole failure in a patient with gastroesophageal reflux disease. Ann Intern Med. 1994 Dec 1;121(11):899–899. doi: 10.7326/0003-4819-121-11-199412010-00021. [DOI] [PubMed] [Google Scholar]
  29. Kadakia S. C., Kikendall J. W., Maydonovitch C., Johnson L. F. Effect of cigarette smoking on gastroesophageal reflux measured by 24-h ambulatory esophageal pH monitoring. Am J Gastroenterol. 1995 Oct;90(10):1785–1790. [PubMed] [Google Scholar]
  30. Katzka D. A., Reynolds J. C., Saul S. H., Plotkin A., Lang C. A., Ouyang A., Jimenez S., Cohen S. Barrett's metaplasia and adenocarcinoma of the esophagus in scleroderma. Am J Med. 1987 Jan;82(1):46–52. doi: 10.1016/0002-9343(87)90376-7. [DOI] [PubMed] [Google Scholar]
  31. Kitchin L. I., Castell D. O. Rationale and efficacy of conservative therapy for gastroesophageal reflux disease. Arch Intern Med. 1991 Mar;151(3):448–454. [PubMed] [Google Scholar]
  32. Klinkenberg-Knol E. C., Festen H. P., Jansen J. B., Lamers C. B., Nelis F., Snel P., Lückers A., Dekkers C. P., Havu N., Meuwissen S. G. Long-term treatment with omeprazole for refractory reflux esophagitis: efficacy and safety. Ann Intern Med. 1994 Aug 1;121(3):161–167. doi: 10.7326/0003-4819-121-3-199408010-00001. [DOI] [PubMed] [Google Scholar]
  33. Klinkenberg-Knol E. C., Meuwissen S. G. Combined gastric and oesophageal 24-hour pH monitoring and oesophageal manometry in patients with reflux disease, resistant to treatment with omeprazole. Aliment Pharmacol Ther. 1990 Oct;4(5):485–495. doi: 10.1111/j.1365-2036.1990.tb00495.x. [DOI] [PubMed] [Google Scholar]
  34. Koelz H. R., Birchler R., Bretholz A., Bron B., Capitaine Y., Delmore G., Fehr H. F., Fumagalli I., Gehrig J., Gonvers J. J. Healing and relapse of reflux esophagitis during treatment with ranitidine. Gastroenterology. 1986 Nov;91(5):1198–1205. doi: 10.1016/s0016-5085(86)80017-8. [DOI] [PubMed] [Google Scholar]
  35. Koop H., Arnold R. Long-term maintenance treatment of reflux esophagitis with omeprazole. Prospective study in patients with H2-blocker-resistant esophagitis. Dig Dis Sci. 1991 May;36(5):552–557. doi: 10.1007/BF01297018. [DOI] [PubMed] [Google Scholar]
  36. Lanas A., Hirschowitz B. I. Significant role of aspirin use in patients with esophagitis. J Clin Gastroenterol. 1991 Dec;13(6):622–627. doi: 10.1097/00004836-199112000-00005. [DOI] [PubMed] [Google Scholar]
  37. Lundell L. Acid suppression in the long-term treatment of peptic stricture and Barrett's oesophagus. Digestion. 1992;51 (Suppl 1):49–58. doi: 10.1159/000200916. [DOI] [PubMed] [Google Scholar]
  38. Lundell L., Backman L., Ekström P., Enander L. K., Falkmer S., Fausa O., Grimelius L., Havu N., Lind T., Lönroth H. Prevention of relapse of reflux esophagitis after endoscopic healing: the efficacy and safety of omeprazole compared with ranitidine. Scand J Gastroenterol. 1991 Mar;26(3):248–256. doi: 10.3109/00365529109025038. [DOI] [PubMed] [Google Scholar]
  39. Marks R. D., Richter J. E. Peptic strictures of the esophagus. Am J Gastroenterol. 1993 Aug;88(8):1160–1173. [PubMed] [Google Scholar]
  40. Marks R. D., Richter J. E., Rizzo J., Koehler R. E., Spenney J. G., Mills T. P., Champion G. Omeprazole versus H2-receptor antagonists in treating patients with peptic stricture and esophagitis. Gastroenterology. 1994 Apr;106(4):907–915. doi: 10.1016/0016-5085(94)90749-8. [DOI] [PubMed] [Google Scholar]
  41. McCord G. S., Clouse R. E. Pill-induced esophageal strictures: clinical features and risk factors for development. Am J Med. 1990 May;88(5):512–518. doi: 10.1016/0002-9343(90)90431-c. [DOI] [PubMed] [Google Scholar]
  42. Miller L. S., Vinayek R., Frucht H., Gardner J. D., Jensen R. T., Maton P. N. Reflux esophagitis in patients with Zollinger-Ellison syndrome. Gastroenterology. 1990 Feb;98(2):341–346. doi: 10.1016/0016-5085(90)90823-j. [DOI] [PubMed] [Google Scholar]
  43. Mittal R. K., Holloway R. H., Penagini R., Blackshaw L. A., Dent J. Transient lower esophageal sphincter relaxation. Gastroenterology. 1995 Aug;109(2):601–610. doi: 10.1016/0016-5085(95)90351-8. [DOI] [PubMed] [Google Scholar]
  44. Orlando R. C., Lacy E. R., Tobey N. A., Cowart K. Barriers to paracellular permeability in rabbit esophageal epithelium. Gastroenterology. 1992 Mar;102(3):910–923. doi: 10.1016/0016-5085(92)90177-z. [DOI] [PubMed] [Google Scholar]
  45. Orlando R. C., Powell D. W., Bryson J. C., Kinard H. B., 3rd, Carney C. N., Jones J. D., Bozymski E. M. Esophageal potential difference measurements in esophageal disease. Gastroenterology. 1982 Nov;83(5):1026–1032. [PubMed] [Google Scholar]
  46. Pera M., Cameron A. J., Trastek V. F., Carpenter H. A., Zinsmeister A. R. Increasing incidence of adenocarcinoma of the esophagus and esophagogastric junction. Gastroenterology. 1993 Feb;104(2):510–513. doi: 10.1016/0016-5085(93)90420-h. [DOI] [PubMed] [Google Scholar]
  47. Richter J. E. Surgery for reflux disease: reflections of a gastroenterologist. N Engl J Med. 1992 Mar 19;326(12):825–827. doi: 10.1056/NEJM199203193261209. [DOI] [PubMed] [Google Scholar]
  48. Robertson D., Aldersley M., Shepherd H., Smith C. L. Patterns of acid reflux in complicated oesophagitis. Gut. 1987 Nov;28(11):1484–1488. doi: 10.1136/gut.28.11.1484. [DOI] [PMC free article] [PubMed] [Google Scholar]
  49. Robinson M., Maton P. N., Allen M. L., Humphries T. J., McIntosh D., Cagliola A. J., Bradstreet T. E. Effect of different doses of omeprazole on 24-hour oesophageal acid exposure in patients with gastro-oesophageal reflux. Aliment Pharmacol Ther. 1991 Dec;5(6):645–651. doi: 10.1111/j.1365-2036.1991.tb00532.x. [DOI] [PubMed] [Google Scholar]
  50. Roesch W. Erosions of the upper gastrointestinal tract. Clin Gastroenterol. 1978 Sep;7(3):623–634. [PubMed] [Google Scholar]
  51. Sabesin S. M., Berlin R. G., Humphries T. J., Bradstreet D. C., Walton-Bowen K. L., Zaidi S. Famotidine relieves symptoms of gastroesophageal reflux disease and heals erosions and ulcerations. Results of a multicenter, placebo-controlled, dose-ranging study. USA Merck Gastroesophageal Reflux Disease Study Group. Arch Intern Med. 1991 Dec;151(12):2394–2400. [PubMed] [Google Scholar]
  52. Sampliner R. E., Garewal H. S., Fennerty M. B., Aickin M. Lack of impact of therapy on extent of Barrett's esophagus in 67 patients. Dig Dis Sci. 1990 Jan;35(1):93–96. doi: 10.1007/BF01537229. [DOI] [PubMed] [Google Scholar]
  53. Sampliner R. E., Hixson L. J., Fennerty M. B., Garewal H. S. Regression of Barrett's esophagus by laser ablation in an anacid environment. Dig Dis Sci. 1993 Feb;38(2):365–368. doi: 10.1007/BF01307557. [DOI] [PubMed] [Google Scholar]
  54. Sandmark S., Carlsson R., Fausa O., Lundell L. Omeprazole or ranitidine in the treatment of reflux esophagitis. Results of a double-blind, randomized, Scandinavian multicenter study. Scand J Gastroenterol. 1988 Jun;23(5):625–632. doi: 10.3109/00365528809093923. [DOI] [PubMed] [Google Scholar]
  55. Simon Thomas J., Berlin Roger G., Gardner Andrea H., Stauffer Laura A., Gould A. Lawrence, Getson Albert J. Self-Directed Treatment of Intermittent Heartburn: A Randomized, Multicenter, Double-Blind, Placebo-Controlled Evaluation of Antacid and Low Doses of an H(2)-Receptor Antagonist (Famotidine). Am J Ther. 1995 May;2(5):304–313. [PubMed] [Google Scholar]
  56. Spechler S. J. Barrett's esophagus: what's new and what to do. Am J Gastroenterol. 1989 Mar;84(3):220–223. [PubMed] [Google Scholar]
  57. Spechler S. J. Epidemiology and natural history of gastro-oesophageal reflux disease. Digestion. 1992;51 (Suppl 1):24–29. doi: 10.1159/000200911. [DOI] [PubMed] [Google Scholar]
  58. Spechler S. J., Goyal R. K. Barrett's esophagus. N Engl J Med. 1986 Aug 7;315(6):362–371. doi: 10.1056/NEJM198608073150605. [DOI] [PubMed] [Google Scholar]
  59. Watson A. Reflux stricture of the oesophagus. Br J Surg. 1987 Jun;74(6):443–448. doi: 10.1002/bjs.1800740603. [DOI] [PubMed] [Google Scholar]
  60. Williamson W. A., Ellis F. H., Jr, Gibb S. P., Shahian D. M., Aretz H. T. Effect of antireflux operation on Barrett's mucosa. Ann Thorac Surg. 1990 Apr;49(4):537–542. doi: 10.1016/0003-4975(90)90298-k. [DOI] [PubMed] [Google Scholar]
  61. Zamost B. J., Hirschberg J., Ippoliti A. F., Furst D. E., Clements P. J., Weinstein W. M. Esophagitis in scleroderma. Prevalence and risk factors. Gastroenterology. 1987 Feb;92(2):421–428. doi: 10.1016/0016-5085(87)90137-5. [DOI] [PubMed] [Google Scholar]
  62. Zaninotto G., DeMeester T. R., Bremner C. G., Smyrk T. C., Cheng S. C. Esophageal function in patients with reflux-induced strictures and its relevance to surgical treatment. Ann Thorac Surg. 1989 Mar;47(3):362–370. doi: 10.1016/0003-4975(89)90374-3. [DOI] [PubMed] [Google Scholar]

Articles from The Yale Journal of Biology and Medicine are provided here courtesy of Yale Journal of Biology and Medicine

RESOURCES